Stock listing
EXEL Stock Price, News, Filings & Events — Exelixis, Inc.
Selected listing: EXEL · NASDAQ · USD · US
This page tracks Exelixis, Inc.'s EXEL:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EXEL:NASDAQ. EXEL:NASDAQ is the stock-level entry point for investors researching Exelixis, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Exelixis, Inc. is a publicly traded biotechnology company based in the United States, focused on developing and commercializing innovative therapies for cancer treatment. The company is listed under the ticker EXEL and has a market capitalization of approximately $14.06 billion. Exelixis aims to improve the lives of patients through its advanced research and development efforts in oncology.
- Ticker
- EXEL:NASDAQ
- Asset type
- Stock
- Market cap
- $13.49B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
Exelixis, Inc. EXEL:NASDAQ stock context
This page tracks Exelixis, Inc.'s EXEL:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following EXEL:NASDAQ. EXEL:NASDAQ is the stock-level entry point for investors researching Exelixis, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Exelixis, Inc. is a publicly traded biotechnology company based in the United States, focused on developing and commercializing innovative therapies for cancer treatment. The company is listed under the ticker EXEL and has a market capitalization of approximately $14.06 billion. Exelixis aims to improve the lives of patients through its advanced research and development efforts in oncology.
Latest news from Exelixis, Inc.
Exelixis to Release Second Quarter 2026 Financial Results on Wednesday, August 5, 2026
July 22, 2026
Exelixis Provides Update on the Phase 3 STELLAR-303 Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in ...
June 22, 2026
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional...
May 30, 2026
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
May 27, 2026
Exelixis Announces Presentations at ASCO 2026 Highlighting Ongoing Studies in Diverse Tumor Types
May 21, 2026
Exelixis, Inc. earnings calls
Exelixis, Inc. (EXEL) Q2 2026 Earnings Call
August 5, 2026 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q1 2026 Earnings Call
May 5, 2026 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q4 2025 Earnings Call
February 10, 2026 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q3 2025 Earnings Call
November 4, 2025 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q2 2025 Earnings Call
July 28, 2025 · Replay with transcript and chapters
Exelixis, Inc. (EXEL) Q1 2025 Earnings Call
May 13, 2025 · Replay with transcript and chapters
Research Exelixis, Inc.
Exelixis, Inc. investor report
Review AI stock analysis and investor report context for EXEL:NASDAQ.
Exelixis, Inc. company profile
View the public company page for Exelixis, Inc. on 6ix.
Exelixis, Inc. news
Read company news and market updates connected to Exelixis, Inc..
Exelixis, Inc. investor events
Find investor webinars, events, and replay context for Exelixis, Inc..
Alternate listings
EX9:GETTEX
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
936718:LSX
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
EX9:TRADEGATE
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
936718:LS
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
0IJO:LSE
GB · USD
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
EX9:FWB
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
1EXEL:MIL
IT · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
E2XE34:BMFBOVESPA
BR · BRL
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
EXEL:BOATS
US · USD
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
EX9:SWB
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
EX9:BX
CH · CHF
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.
EX9:DUS
DE · EUR
Alternate listing for Exelixis, Inc.; the primary context on this page is EXEL:NASDAQ.